What to invest in on the stock market? Five stocks to have on your radar in January 2026

Boom

This Polish company based in Katowice, specializing in the provision of services for the coal industry and the production of mining machinery and equipment, was listed in a similar list in December as the antihero of November. Then the stock market dropped by 45%. In December, or rather at the very end of the month and year, there was a 180-degree turn and share prices skyrocketed. This way Bumech has become one of the strongest companies on the stock exchange.

See also: There is an important agreement for miners. Here's what it contains

Between December 29 and January 5, Bumech's capitalization increased by almost 90% at its peak.

The rollercoaster on the shares of the Katowice company was related to the loud protest of miners in PG “Silesia”. When it turned out that the Minister of Energy had concluded an agreement with the mine's representatives and there was a chance to support its operation and protect miners, the share price skyrocketed.

In the context of the action, it is worth continuing to observe the events around Silesia. The government side mediating in the case stated that it would take steps by February 28, 2026 to develop legislative solutions enabling the implementation of the concluded agreement.

Cyfrowy Polsat

The end of 2025 was very exciting for one of the largest media groups in Poland. After the court in Liechtenstein resolved the issue of succession in the Solorz family, Zygmunt Solorz receded into the background, and his children appeared at the forefront. Therefore, this happened a cadre earthquake throughout the Solorz empire.

See also: The Solorz family empire underwent a personnel earthquake. See a summary of all changes

The largest listed company of one of the richest families in Poland is Cyfrowy Polsat. Investors reacted to the whole mess with optimism. Within three days, share prices increased by approximately 20%. and remain at a level above PLN 12 per share at the beginning of 2026.

The company's representatives announced a new stage in its operations, strengthening corporate supervision, improving efficiency and management standards. The goal is to “regain the position of a champion of the Polish economy, create a modern organization using the latest technologies, quickly implement solutions based on artificial intelligence, and, above all, confirm credibility in financial markets and attractiveness for investors.”.

Molecure

In January 2026, it is worth following the actions of not only the stock market heroes at the end of the previous year, but also promising companies selected by brokerage house experts. A unique example is the biotechnology company Molecure (formerly OncoArendi Therapeutics), which is engaged in the discovery and development of innovative small-molecule drugs that target proteins and mRNA functions in the treatment of diseases, including: cancer and inflammation.

In the latest recommendation of the Trigon Brokerage House, Molecure shares were valued at PLN 18. Meanwhile, at the end of 2025, they could be purchased on the stock exchange for PLN 6.60. This gives the potential for growth of approximately 170%. This is a huge overstatement, not normally found in recommendations, suggesting a huge underestimation of the company's value by the market.

It is worth adding that this is not an anomaly of one recommendation. A moment earlier, in November 2025, analysts of another brokerage house – Noble Securities – valued one Molecure share at PLN 17.60.

However, investors still do not believe in such great potential. The last month's balance for shares was negative. Quotations fell by about 4%. In three months, Molecure's capitalization decreased by 10 percent, and in one year – by 25 percent.

Scope Fluidics

The situation is similar at Scope Fluidics – a Polish technology company from the med-tech sector that specializes in developing innovative medical diagnostic systems using microflow technology. The main pillar of its activities in 2026 is the development of the BacterOMIC system, used for quick and precise determination of drug susceptibility of microorganisms.

Scope Fluidics shares perform averagely on the stock market. The last month's balance is slightly negative (-3.5%), and over the three months the prices have fallen by over 10%. around PLN 142 per piece. Meanwhile, in December, an Ipopema analyst valued them at almost PLN 211. If the stock exchange rate reached this level, it would mean a jump of almost 50%.

“Scope may be a dark horse in the healthcare sector in 2026.” – says Łukasz Kosiarski, an Ipopema analyst. “The most advanced BacterOMIC project should receive its first registration soon and enter the market next year and start generating the first revenues. Importantly, the company has selected a transaction advisor in the process of acquiring a strategic investor, and M&A story may, in our opinion, be a strong driver of Scope's share price growth while waiting for the transaction,” he comments.

He notes that “Scope Fluidics quite unexpectedly carried out a share issuewhich depressed the stock price, but on the other hand, completely satisfied the financial needs of the company i disarmed the risk of share issuance as a factor limiting the price increase“.

Benefit Systems

An example of a company whose share prices on the stock exchange are increasing, and which has set the bar much higher thanks to recommendations, is Benefit Systems. The Polish company, known mainly for being an operator of employee benefits in the form of MultiSport cards, grew on the stock exchange by 7% in one month and by 14% in three months.

The Benefit Systems quotations chart shows that investors still have an appetite for shares, which at the beginning of January were valued at approximately PLN 3,600 per share. Meanwhile analysts of the Trigon Brokerage House estimate their target value at PLN 5,150. Currently, the potential rate of return is 43%.

“The first full quarter of consolidation of the fitness chain revealed that the chain operates with higher than expected profitability and the effect of seasonality is lower. At the same time, in accordance with the guidelines, the network expansion in 2026 will be faster than expected” – says Grzegorz Kujawski, Trigon analyst.

See also: Türkiye agreed to a large investment by the Polish company. $420 million on the table

He adds that an increase in the number of B2B cards in Poland and an increase in the activity of MultiSport users confirmed that “consumer trends, including a greater share of younger generation cohorts, support the company's market environment despite demographic challenges.”

“In our analysis of companies from the Central and Eastern European region, Benefit Systems is a consumer company with the highest current growth potential and a strong growth profile supported by consumer trends,” we read in the Trigon report.

Note: The information contained in the text is for informational purposes only and does not constitute a recommendation to buy or sell financial products. This text does not constitute an investment recommendation or investment advisory activities within the meaning of §3 of the Regulation of the Minister of Finance of October 19, 2005 on information constituting recommendations regarding financial instruments, their issuers or issuers (Journal of Laws 2005, No. 206, item 1715).

Author: Damian Słomski, journalist of Business Insider Polska